Biopharmaceutical firm AnorMED
Things started to heat up for AnorMED last year, when a large institutional shareholder, upset with management's direction for the company, launched a campaign to unseat the current leadership. The shareholder feared that AnorMED would partner the company's lead drug, MOZOBIL, intended for stem cell transplants, too cheaply, and was also angered by dilutive financing done near the stock's 52-week lows.
Motley Fool Hidden Gems
The interesting part? Apparently, Genzyme privately offered $8.55 per share for the company several months ago, but management didn't like the offer. AnorMED never publicly disclosed the offer, and I wonder what role, if any, the Genzyme offer played in the ousting of the previous board of directors. Because AnorMED management rejected the earlier offer, Genzyme went public with its new attempt at a hostile takeover.
Was spurning Genzyme a smart move? We should know in a few months. MOZOBIL top-line trial results are expected in the first half of 2007, and if the trial is successful, the company plans to file a New Drug Application with the Food and Drug Administration sometime in the second half of 2007. Since AnorMED's other compounds in development are all early-stage drugs, years away from any sort of marketing approval, the Genzyme offer was most likely based upon a favorable opinion of MOZOBIL.
AnorMED's directors are the company's largest shareholders, owning 24.4% of outstanding shares. That means Genzyme probably can't wrest control of AnorMED away from the current board members without more tempting. The company also enacted an ironically dubbed "shareholder rights plan," which prevents any individual shareholder from owning more than 20% of the company for the next six months. If that doesn't prevent any immediate hostile takeover by Genzyme, it should at least allow AnorMED's current board to challenge such a maneuver in court.
Biotech. Nanotech. Med-tech. If it ends in "tech," chances are you'll find it covered in Motley Fool Rule Breakers . Join David Gardner's search for the next ultimate growth stock with a free 30-day trial subscription .